Form D · Biotechnology
VYNE Therapeutics Inc.
Bridgewater, NJ · CIK 0001566044
Offering snapshot reported Nov 16, 2023 · SEC filing
- Reported sold
- $88.2M Offering amount: $88.2M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 1, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 16, 2023 | Initial | $88,151,508 | No comparison | 19 | SEC filing |
| Nov 18, 2022 | Initial | $300,000 | No comparison | 1 | SEC filing |
| Jul 28, 2017 | Initial | $50,500,001 | No comparison | 11 | SEC filing |
| Jan 7, 2013 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $5.04M
- Finders' fees
- $0
- Form D file number
- 021-497484
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| LifeSci Capital LLC | 168404 |
Source: Form D, filed Nov 16, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sharon Barbari | Director |
| Steven Basta | Director |
| Anthony Bruno | Director |
| Albert Cha | Director |
| David Collier | Director |
| John Creecy | Director |
| David Domzalski | Director, Executive |
| Ted Ebel | Director |
| Mutya Harsch | Executive |
| James Larrick | Director, Executive |
| Patrick Lepore | Director |
| Ketan Patel | Director |
| Andrew Perlman | Director |
| Aaron Royston | Director |
| Elisabeth Sandoval | Director |
| Edward Schnipper | Director |
| Iain Stuart | Executive |
| Scott Whitcup | Director |
| Tyler Zeronda | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
685 Route 202/206 N., Suite 301
Bridgewater, NJ, 08807
Bridgewater, NJ, 08807